Balyasny Asset Management
INFI

Balyasny Asset Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Balyasny Asset Management’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,611
Closed -$25K – 3366
2022
Q3 		$25K Buy
20,611
+3,488
+20% +$3.76K ﹤0.01% 2556
2022
Q2 		$11K Buy
+17,123
New +$13.1K ﹤0.01% 2572
2021
Q2 		– Sell
-16,873
Closed -$54K – 2492
2021
Q1 		$54K Buy
+16,873
New +$56.3K ﹤0.01% 1682
2018
Q1 		– Sell
-19,325
Closed -$39K – 2417
2017
Q4 		$39K Buy
+19,325
New +$40.1K ﹤0.01% 2020
2015
Q1 		– Sell
-412,656
Closed -$6.97M – 1113
2014
Q4 		$6.97M Buy
+412,656
New +$6.01M 0.06% 375
2014
Q3 		– Sell
-275,421
Closed -$3.51M – 892
2014
Q2 		$3.51M Buy
+275,421
New +$2.87M 0.04% 451

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Balyasny Asset Management's INFI Position: Q4 2022 in Review

Balyasny Asset Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2022, closing a stake of 20,611 shares — an estimated $25K sold.

Balyasny Asset Management first reported a position in INFI in Q2 2014 and held it in 6 quarters. The position peaked at $6.97M in Q4 2014. 68 funds tracked by Wall St. Rank hold INFI as of Q4 2022.

  • Balyasny Asset Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 20,611 Infinity Pharmaceuticals, Inc. shares in Q4 2022, an estimated $25K.
  • Balyasny Asset Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2014 and held it in 6 quarters.
  • Balyasny Asset Management's Infinity Pharmaceuticals, Inc. position peaked at $6.97M in Q4 2014.
  • 68 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.